Evidence map›Paper›PMID 33999275›Full record

ArticleClinical and experimental nephrology2021

Low-GDP, pH-neutral solutions preserve peritoneal endothelial glycocalyx during long-term peritoneal dialysis.

Naoya Sugiyama, Mitsuhiro Tawada, Ting Sun, Yasuhiro Suzuki, Hiroshi Kinashi, Makoto Yamaguchi, Takayuki Katsuno, Jan Aten, Carmen A Vlahu, Toin H van Kuppevelt and 5 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Observational
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Naoya SugiyamaDepartment of Nephrology and Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Mitsuhiro TawadaDepartment of Nephrology and Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Ting SunDepartment of Nephrology and Rheumatology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.
Yasuhiro SuzukiDepartment of Nephrology and Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroshi KinashiDepartment of Nephrology and Rheumatology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.
Makoto YamaguchiDepartment of Nephrology and Rheumatology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.
Takayuki KatsunoDepartment of Nephrology and Rheumatology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.
Jan AtenDepartment of Pathology, Amsterdam University Medical Center (Location AMC), University of Amsterdam, Amsterdam, The Netherlands.
Carmen A VlahuDepartment of Pathology, Amsterdam University Medical Center (Location AMC), University of Amsterdam, Amsterdam, The Netherlands.
Toin H van KuppeveltDepartment of Biochemistry, Radboud University Medical Center, Nijmegen, The Netherlands.
Yoshifumi TakeiDepartment of Medicinal Biochemistry, Aichi Gakuin University School of Pharmacy, Nagoya, Japan.
Takuji IshimotoDepartment of Nephrology and Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shoichi MaruyamaDepartment of Nephrology and Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masashi MizunoDepartment of Nephrology and Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yasuhiko ItoDepartment of Nephrology and Rheumatology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan. yasuito@aichi-med-u.ac.jp.ORCID http://orcid.org/0000-0002-9676-6961
Aichi Medical University · JPNagoya University · JPAmsterdam University Medical Centers · NLAichi Gakuin University · JPRadboud University Nijmegen · NL

Funding

Ministry of Education 18K08258
6 · The paper itself

Abstract

backgroundDuring peritoneal dialysis (PD), solute transport and ultrafiltration are mainly achieved by the peritoneal blood vasculature. Glycocalyx lies on the surface of endothelial cells and plays a role in vascular permeability. Low-glucose degradation product (GDP), pH-neutral PD solutions reportedly offer higher biocompatibility and lead to less peritoneal injury. However, the effects on the vasculature have not been clarified.

methodsPeritoneal tissues from 11 patients treated with conventional acidic solutions (acidic group) and 11 patients treated with low-GDP, pH-neutral solutions (neutral group) were examined. Control tissues were acquired from 5 healthy donors of kidney transplants (control group). CD31 and ratio of luminal diameter to vessel diameter (L/V ratio) were evaluated to identify endothelial cells and vasculopathy, respectively. Immunostaining for heparan sulfate (HS) domains and Ulex europaeus agglutinin-1 (UEA-1) binding was performed to assess sulfated glycosaminoglycans and the fucose-containing sugar chain of glycocalyx.

resultsCompared with the acidic group, the neutral group showed higher CD31 positivity. L/V ratio was significantly higher in the neutral group, suggesting less progression of vasculopathy. Both HS expression and UEA-1 binding were higher in the neutral group, whereas HS expression was markedly more preserved than UEA-1 binding in the acidic group. In vessels with low L/V ratio, which were found only in the acidic group, HS expression and UEA-1 binding were diminished, suggesting a loss of glycocalyx.

conclusionPeritoneal endothelial glycocalyx was more preserved in patients treated with low-GDP, pH-neutral solution. The use of low-GDP, pH-neutral solutions could help to protect peritoneal vascular structures and functions.

Indexed as

Peritoneal DialysisAdultAgedBiopsyCapillariesDialysis SolutionsEndothelial CellsFemaleGlucoseGlycocalyxHeparan SulfateHumansHydrogen-Ion ConcentrationMaleMiddle AgedPeritoneumDialysis SolutionsGlucoseHeparan SulfatePECAM1 protein, humanPlant LectinsPlatelet Endothelial Cell Adhesion Molecule-1Ulex europaeus lectinsAcidicEndothelial glycocalyxPeritoneal dialysispH-neutralPostcapillary venuleVasculopathy

Identifiers

PMID33999275
OpenAlexW3161844311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.